Giulia Zamprogna

Varese, 21100, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 20 publications

Autoimmune Cytopenias in Chronic Lymphocytic Leukemia.

Autoimmune Cytopenias in Chronic Lymphocytic Leukemia.

Journal: Hematology/oncology clinics of North America
Published: July 01, 2025

Ibrutinib or non-BTK inhibitor therapy in relapsed Waldenström macroglobulinemia: a real-life multicenter Italian study.

Ibrutinib or non-BTK inhibitor therapy in relapsed Waldenström macroglobulinemia: a real-life multicenter Italian study.

Journal: Blood advances
Published: June 13, 2025

Kinetics of lymphocytosis in naïve chronic lymphocytic leukemia patients treated with covalent Bruton's tyrosine kinase inhibitors: An Italian multicenter real-life experience.

Kinetics of lymphocytosis in naïve chronic lymphocytic leukemia patients treated with covalent Bruton's tyrosine kinase inhibitors: An Italian multicenter real-life experience.

Journal: HemaSphere
Published: May 28, 2024

First-line treatment of Waldenström's macroglobulinemia in Italy: A multicenter real-life study on 547 patients to evaluate the long-term efficacy and tolerability of different chemoimmunotherapy strategies.

First-line treatment of Waldenström's macroglobulinemia in Italy: A multicenter real-life study on 547 patients to evaluate the long-term efficacy and tolerability of different chemoimmunotherapy strategies.

Journal: American journal of hematology
Published: May 03, 2024

Patients' preferences for chronic lymphocytic leukemia treatment: The CHOICE study.

Patients' preferences for chronic lymphocytic leukemia treatment: The CHOICE study.

Journal: Hematological oncology
Published: May 26, 2023

Next Generation BTK Inhibitors in CLL: Evolving Challenges and New Opportunities.

Next Generation BTK Inhibitors in CLL: Evolving Challenges and New Opportunities.

Journal: Cancers
Published: December 31, 2022

Tixagevimab/Cilgavimab Pre-exposure Prophylaxis in Patients With Lymphoproliferative Disorders on BTKi.

Tixagevimab/Cilgavimab Pre-exposure Prophylaxis in Patients With Lymphoproliferative Disorders on BTKi.

Journal: HemaSphere
Published: December 09, 2022

How COVID-19 pandemic changed our attitude to venetoclax-based treatment in chronic lymphocytic leukemia.

How COVID-19 pandemic changed our attitude to venetoclax-based treatment in chronic lymphocytic leukemia.

Journal: Leukemia & lymphoma
Published: March 28, 2022

Coexisting conditions and concomitant medications do not affect venetoclax management and survival in chronic lymphocytic leukemia.

Coexisting conditions and concomitant medications do not affect venetoclax management and survival in chronic lymphocytic leukemia.

Journal: Therapeutic advances in hematology
Published: March 11, 2022

SOHO State of the Art Updates and Next Questions: What is Fitness in the Era of Targeted Agents?

SOHO State of the Art Updates and Next Questions: What is Fitness in the Era of Targeted Agents?

Journal: Clinical lymphoma, myeloma & leukemia
Published: September 08, 2021

Do age, fitness, and concomitant medications influence management and outcomes of patients with CLL treated with ibrutinib?

Do age, fitness, and concomitant medications influence management and outcomes of patients with CLL treated with ibrutinib?

Journal: Blood advances
Published: March 22, 2021

Identification of a Candidate Gene Set Signature for the Risk of Progression in IgM MGUS to Smoldering/Symptomatic Waldenström Macroglobulinemia (WM) by a Comparative Transcriptome Analysis of B Cells and Plasma Cells.

Identification of a Candidate Gene Set Signature for the Risk of Progression in IgM MGUS to Smoldering/Symptomatic Waldenström Macroglobulinemia (WM) by a Comparative Transcriptome Analysis of B Cells and Plasma Cells.

Journal: Cancers
Published: February 15, 2021
Showing 1-12 of 20

Last Updated: 09/26/2026